Pharmacoeconomic review report. AbobotulinumtoxinA (Dysport therapeutic) (Ipsen Biopharmaceuticals Canada, Inc.).
AbobotulinumtoxinA (aboBoNTA, Dysport Therapeutic) is a botulinum neurotoxin subtype indicated to reduce the subjective symptoms and objective signs of cervical dystonia (CD, spasmodic torticollis) in adults, and is available in single-use vials of 300 U and 500 U at submitted prices of $428.40 and...
Saved in:
| Online Access: |
http://www.ncbi.nlm.nih.gov/books/NBK535069/ Full text |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Ottawa (ON) :
Canadian Agency for Drugs and Technologies in Health,
2017
|
| Series: | Common drug review clinical review report.
|
| Subjects: |
